ARTHROPLASTY
Oral edoxaban vs. subcutaneous enoxaprain for VTE prophylaxis after TKA
This report has been verified
by one or more authors of the
original publication.
Thromb Res. 2014 Dec;134(6):1198-204
716 Japanese and Taiwanese patients undergoing total knee arthroplasty were randomized to either oral edoxaban 30mg or subcutaneous enoxaparin 2000IU for 11-14 days after surgery. The purpose of this study was to compare efficacy and safety of edoxaban to that of enoxaparin. Venous thromboembolic events and bleeding outcomes were assessed for 25-35 days after the last administration of study drug. The edoxaban group demonstrated a significant lower incidence of composite VTE when compared to enoxaparin. Incidence of major and clinically-relevant nonmajor bleeding was not significantly different between groups.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
